DOI: https://doi.org/10.26641/2307-0404.2020.2.206360

Analysis of ANRIL gene polymorphism rs4977574 association with kidney cancer development in Ukrainian population.

A. D. Volkogon, V. Yu. Harbuzova, A. V. Ataman

Abstract


ANRIL (Antisense Non-coding RNA in the INK4 Locus, also known as CDKN2B-AS1) – 3.8-kb long non-coding RNA transcribed from the antisense strand of INK4b-ARF-INK4a gene cluster. It is known that ANRIL overexpression is associated with development of oncological pathologies of different localization. In addition, there are a number of studies devoted to role of ANRIL genetic polymorphism in emergence and progression of tumors, including tumors of genitourinary system. The aim of the study was to check the possible association between ANRIL gene polymorphism rs4977574 and kidney cancer development in representatives of Ukrainian population. Whole venous blood of 101 patients with clear cell renal cell carcinoma (CCRCC) (42 women and 59 men) and 100 patients without oncology history (34 women and 66 men) was used in the study. DNA from blood white cells was extracted using GeneJET Whole Blood Genomic DNA Purification Mini Kit (Thermo Fisher Scientific, USA). Genotyping of rs4977574 ANRIL gene polymorphic locus was performed using real-time polymerase chain reaction (real-time PCR) method in the presence of TaqMan assay C_31720978_30. The mathematical data were processed using the SPSS software package (version 17.0). P values <0.05 were considered as statistically significant. It was found that difference in rs4977574-genotype distribution between patients with CCRCC and control persons was absent in general group (P=0.216). At the same time, the statistical analysis stratified by gender showed that both in female and male subjects rs4977574-genotypes frequency also did not differ significantly between comparison groups (P=0.526 and P=0.160, respectively). However, after adjusting for age, body mass index, and smoking habits statistically significant association between rs4977574 ANRIL gene polymorphism and risk of kidney cancer development was detected in male subjects under superdominant inheritance model (P=0.049). It was revealed that heterozygotes (AG-genotype) have 2.17-fold  higher risk of CCRCC development (95% CI=1.005-4.695) compared to patients with AA- and GG-genotypes. In summary, this is the first report about ANRIL gene polymorphisms association with kidney cancer. Obtained results revealed that rs4977574 is related to kidney cancer risk only in Ukrainian men. Male individuals with AG-genotype have higher risk of CCRCC development compared to AA- and GG-genotypes carriers.

Keywords


long non-coding RNA; ANRIL; gene polymorphism; kidney cancer

Full Text:

PDF (English)

References


[About the Approving of Conducting of Medi­cines Clinical Trials Procedure and Expertise of Clinical Trials Materials, and the Model Regulations on Ethics Committees: Order of the Ministry of Health of Ukraine No. 690]. 2009. September 23. Ukrainian.

Khorshidi H, Taheri M, Noroozi R, Sarrafza­deh S, Sayad A, Ghafouri-Fard S. ANRIL Genetic Va­riants in Iranian Breast Cancer Patients. Cell J. 2017;19(Suppl 1):72-78. doi: https://doi.org/10.22074/cellj.2017.4496

Taheri M, Pouresmaeili F, Omrani MD, Habi­bi M, Sarrafzadeh S, Noroozi R, et al. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. Biomark Med. 2017;11(5):413-22. doi:https://doi.org/10.2217/bmm-2016-0378

Gong WJ, Yin J, Li XP, Fang C, Xiao D, Zhang W, et al. Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour Biol. 2016;37(6):8349-58. doi: https://doi.org/10.1007/s13277-015-4497-5

Czarnecka A, Niedzwiedzka M, Porta C, Szczy­lik C. Hormone signaling pathways as treatment targets in renal cell cancer (Review). Int J Oncol. 2016;48(6):2221-35. doi: https://doi.org/10.3892/ijo.2016.3460

Dianatpour A, Ghafouri-Fard S. The Role of Long Non Coding RNAs in the Repair of DNA Double Strand Breaks. Int J Mol Cell Med. 2017;6(1):1-12.

Meseure D, Vacher S, Alsibai KD, Nicolas A, Che­mlali W, et al. Expression of ANRIL-Poly­comb Comp­lexes-CDKN2A/B/ARF Genes in Breast Tu­mors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value. Mol Cancer Res. 2016;(7):623-33.

Gamell C, Ginsberg D, Haupt S, Haupt Y. New insights on the regulation of INK4/ARF locus expression. Oncotarget. 2017;8(63):106147-8. doi: https://doi.org/10.18632/oncotarget.22258

Liu P, Zhang M, Niu Q, Zhang F, Yang Y, Jiang X. Knockdown of long non-coding RNA ANRIL inhibits tumorigenesis in human gastric cancer cells via microRNA-99a-mediated down-regulation of BMI1. Braz J Med Biol Res. 2018;51(10):e6839. doi: https://doi.org/10.1590/1414-431x20186839

Kong Y, Hsieh C, Alonso L. ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease. Front Endocrinol (Lausanne). 2018;9:405. doi: https://doi.org/10.3389/fendo.2018.00405

Zhu H, Li X, Song Y, Zhang P, Xiao Y, Xing Y. Long non-coding RNA ANRIL is up-regulated in bladder cancer and regulates bladder cancer cell proliferation and apoptosis through the intrinsic pathway. Biochem Biophys Res Commun. 2015;467(2):223-28. doi: https://doi.org/10.1016/j.bbrc.2015.10.002

Fanelli G, Gasparini P, Coati I, Cui R, Pakula H, Chowdhury B. Long-noncoding RNAs in gastro­eso­phageal cancers. Noncoding RNA Res. 2018;3(4):195-212. doi: https://doi.org/10.1016/j.ncrna.2018.10.001

Zhai W, Ma J, Zhu R, Xu C, Zhang J, Chen Y, et al. MiR-532-5p suppresses renal cancer cell pro­liferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis. Br J Cancer. 2018;119(5):591-604. doi: https://doi.org/10.1038/s41416-018-0196-5

Tritto V, Ferrari L, Esposito S, Zuccotti P, Bian­chessi D, Natacci F. Non-Coding RNA and Tumor Deve­lopment in Neurofibromatosis Type 1: ANRIL rs2151280 Is Associated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients. Genes (Basel). 2019;10(11): E892. doi: https://doi.org/10.3390/genes10110892

Zhao B, Lu Y, Yang Y, Hu L, Bai Y, Li R, et al. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-β1/ Smad signaling pathway. Cancer Biomark. 2018;21(3):613-620. doi: https://doi.org/10.3233/CBM-170683

Poi M, Li J, Sborov D, VanGundy Z, Cho Y, Lamprecht M, et al. Polymorphism in ANRIL is asso­ciated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol Carcinog. 2017;56(7):1722-32. doi: https://doi.org/10.1002/mc.22626

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles R. Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. Eur Urol. 2017;pii: S0302-2838(17)31001-1. doi: https://doi.org/10.1016/j.eururo.2017.11.016

Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regu­lators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44(D1):D877-881. doi: https://doi.org/10.1093/nar/gkv1340


GOST Style Citations


  1. Про затвердження Порядку проведення клініч­них випробувань лікарських засобів та експертизи матеріалів клінічних випробувань і Типового положення про комісії з питань етики: наказ МОЗ України № 690 від 23.09.2009 р.
  2. ANRIL Genetic Variants in Iranian Breast Cancer Patients / H. Khorshidi et al. Cell J. 2017. Vol. 19, No. 1. P. 72-78. DOI: https://doi.org/10.22074/cellj.2017.4496
  3. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population / M. Taheri et al. Biomark Med. 2017. Vol. 11, No.5. P. 413-422. DOI: https://doi.org/10.2217/bmm-2016-0378
  4. Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response / W. Gong et al. Tumour Biol. 2016. Vol. 37, No. 6. P. 8349-8358. DOI: https://doi.org/10.1007/s13277-015-4497-5
  5. Czarnecka A., Niedzwiedzka M., Porta C., Szczy­lik C. Hormone signaling pathways as treatment targets in renal cell cancer: review. Int J Oncol. 2016. Vol. 48, No. 6. P. 2221-2235. DOI: https://doi.org/10.3892/ijo.2016.3460
  6. Dianatpour A., Ghafouri-Fard S. The Role of Long Non Coding RNAs in the Repair of DNA Double Strand Breaks. Int J Mol Cell Med. 2017. Vol. 6, No. 1. P. 1-12.
  7. Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Inde­pendent Prognostic Value / D. Meseure et al. Mol. Cancer Res. 2016. Vol. 7. P. 623-633. DOI: https://doi.org/10.1158/1541-7786.MCR-15-0418
  8. Gamell C., Ginsberg D., Haupt S., Haupt Y. New insights on the regulation of INK4/ARF locus expression. Oncotarget. 2017. Vol. 8, No. 63. P. 106147-106148. DOI: https://doi.org/10.18632/oncotarget.22258
  9. Knockdown of long non-coding RNA ANRIL inhibits tumorigenesis in human gastric cancer cells via microRNA-99a-mediated down-regulation of BMI1 / P. Liu et al. Braz J Med Biol Res. 2018. Vol. 51, No. 10. e6839. DOI: https://doi.org/10.1590/1414-431x20186839
  10. Kong Y., Hsieh C., Alonso L. ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease. Front Endocrinol (Lausanne). 2018. Vol. 9. P. 405. DOI: https://doi.org/10.3389/fendo.2018.00405
  11. Long non-coding RNA ANRIL is up-regulated in bladder cancer and regulates bladder cancer cell proliferation and apoptosis through the intrinsic pathway / H. Zhu et al. Biochem Biophys Res Commun. 2015. Vol. 467, No. 2. P. 223-228. DOI: https://doi.org/10.1016/j.bbrc.2015.10.002
  12. Long-noncoding RNAs in gastroesophageal cancers / G. Fanelli et al. Noncoding RNA Res. 2018. Vol. 3, No. 4. P. 195-212. DOI: https://doi.org/10.1016/j.ncrna.2018.10.001
  13. MiR-532-5p suppresses renal cancer cell pro­liferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis / W. Zhai et al. Br J Cancer. 2018. Vol. 119, No. 5. P. 591-604. DOI: https://doi.org/10.1038/s41416-018-0196-5
  14. Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: ANRIL Rs2151280 Is As­sociated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients / V. Tritto et al. Genes (Basel). 2019. Vol. 10, No. 11. E892. DOI: https://doi.org/10.3390/genes10110892
  15. Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-β1/ Smad signaling pathway / B. Zhao et al. Cancer Biomark. 2018. Vol. 21, No. 3. P. 613-620. DOI: https://doi.org/10.3233/CBM-170683
  16. Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant / M. Poi et al. Mol Carcinog. 2017. Vol. 56, No. 7. P. 1722-1732. DOI: https://doi.org/10.1002/mc.22626
  17. Updated European Association of Urology Gui­delines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer / T. Powles et al. Eur Urol. 2017. pii. S0302-2838(17)31001-1. DOI: https://doi.org/10.1016/j.eururo.2017.11.016
  18. Ward L. D., Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016. Vol. 44, No. 1. P. 877-881. DOI: https://doi.org/10.1093/nar/gkv1340




 

This work is licensed under a Creative Commons Attribution 4.0 International License